News and Trends 22 Aug 2022 Drug to treat rare kidney disease to be reviewed by EMA The European Medicines Agency (EMA) has agreed to review a conditional marketing authorization (CMA) application for a drug to treat a rare kidney disorder. The news was announced today (August 21) by CSL Vifor and Travere Therapeutics Inc, and, if approved, the companies say sparsentan will address a significant unmet need in treating IgA nephropathy […] August 22, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 22 Aug 2022 Roche launches COVID-19 test to detect emerging variant of interest Roche and its subsidiary TIB Molbiol have developed a COVID-19 test for researchers that detects and differentiates the latest sub-variant of interest BA.2.75. The test specifically targets two of the known unique mutations in BA.2.75, which allows clear differentiation against other notable subvariants. “Roche is pleased to have developed a test for researchers that provides […] August 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Aug 2022 Vaderis emerges from stealth to start HTT trial Vaderis Therapeutics AG, a clinical stage biotech company focused on developing treatments for rare diseases associated with vascular malformations, has emerged from stealth. The company has also started its INSIGHT proof-of-concept clinical trial in patients suffering from hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome. About HHT HHT is a disorder where some blood […] August 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 ADC Therapeutics announces series of financial moves including $175M loan from Owl Rock ADC Therapeutics has announced a series of major strategic transactions involving hundreds of millions of dollars allowing it to advance its lead candidate and pipeline drugs. The Swiss company has entered into a new $175 million senior secured loan with certain funds of Owl Rock – a division of Blue Owl Capital, Inc. and funds […] August 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 15 Aug 2022 Roche announces influenza drug approval and new COVID test Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours. This marks […] August 15, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 Endogena Therapeutics to start clinical stage with treatment for blindness caused by retinitis pigmentosa Endogena Therapeutics Inc. has announced the first patient has been treated in a phase 1/2a clinical study of its lead product, EA-2353, a photoreceptor regeneration treatment for retinitis pigmentosa (RP). RP is a group of inherited diseases causing slow and progressive retinal degeneration and loss of vision, for which there is currently no treatment for […] July 12, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 May 2022 The Top European Biotech Investments in April 2022 Private biotech investments in Europe were on a steady decline in April 2022 as biotech public markets continued to disappoint. The top funding rounds were dominated by UK and Swiss firms targeting genetic diseases and cancer. April 2022 provided no relief for the European biotech industry as public stock markets remain anemic. Though flush with […] May 12, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jan 2022 AI Hot in Healthcare Despite IBM’s Watson Health Pullout Earlier this week, the tech giant IBM sold off chunks of its once-promising artificial intelligence (AI)-guided division Watson Health. Despite this setback, European firms see a bright future for the use of AI in healthcare. The tech giant IBM hit the headlines this week when it sold off parts of Watson Health — a division […] January 28, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2022 Swiss Startup Signs on with Novo Nordisk to Discover Obesity Treatments The Swiss startup EraCal Therapeutics has signed a research partnership with the Danish pharmaceutical giant Novo Nordisk to search for treatments controlling food intake and other factors contributing to obesity. Under the joint project, EraCal and Novo Nordisk will research targets for obesity treatments by identifying molecules that can control appetite and improve metabolic health. […] January 17, 2022 - 3 minutesmins - By Dan Samorodnitsky Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jan 2022 Biotech Startup Incubators Prepare to Cash in on Record VC Funding Venture capital funding broke records in the biotech industry in 2021. Leading startup incubators from across Europe share their plans to make the most of this trend in 2022, with expectations for big returns and expansion in the works. In spite of financial volatility resulting from the Covid-19 pandemic, the year 2021 broke records for […] January 13, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2021 Longevity Foundation to Fund Geroscience Research with €860M The newly-created Longevity Science Foundation aims to extend the human lifespan to more than 120 years by channeling over €860M ($1B) into early-stage geroscience research in the next decade. Experts say that’s a worthy if complex goal. Based in Zug, Switzerland, the Longevity Science Foundation will prioritize four areas of research: personalized medicine, therapeutics, artificial […] October 11, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 15 Oct 2020 Swiss Biotech Launches Amidst Hot Streak for Rare Autoimmune Disease Swiss biotech Chord Therapeutics launched this week with a €13.7M Series A, becoming the latest company to tackle the rare condition neuromyelitis optica, for which three therapies have been approved in less than a year. Neuromyelitis optica spectrum disorders, previously also known as Devic disease, affect up to 2 in 100,000 people around the world. […] October 15, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email